Posted by Michael Wonder on 02 Jun 2021
Scynexis announces FDA approval of Brexafemme (ibrexafungerp tablets) as the first and only oral non-azole treatment for vaginal yeast infections
2 June 2021 - Approval of Brexafamme (ibrexafungerp) represents the first approved drug in a novel antif-ungal class in more than 20 years.
Scynexis today announced that the U.S. FDA has approved Brexafemme (ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis, also known as vaginal yeast infection.
